Sheldon J. Freedman

12-Month Outcomes From a Randomized, Sham-Controlled Trial Evaluating a Novel Prostatic Urethral Stent for the Treatment of Benign Prostatic Hyperplasia

Steven A. Kaplan, Sijo J. Parekattil, Ning Wu, Brian C. Mazzarella et autres

PURPOSE: The ProVee System for benign prostatic hyperplasia is a new generation permanent prostatic urethral stent for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. ProVIDE is a prospective, randomized, double-blind, sham-controlled study evaluating the safety and effectiveness …

us, ie, ca, gb (code pays fourni par la source)

12-MONTH OUTCOMES FROM A RANDOMIZED, SHAM CONTROLLED STUDY EVALUATING A NOVEL PROSTATIC URETHRAL STENT FOR THE TREATMENT OF BPH

Steven A. Kaplan, Sijo J. Parekattil, Ning Wu, Brian C. Mazzarella et autres

PD08-07 PATIENTS DISSATISFIED WITH BPH MEDICATION IN THE IMPACT RCT DEMONSTRATE WORSE PATIENT EXPERIENCE AND SLEEP QUALITY BEFORE CROSSING OVER TO UROLIFT PUL

Dean Elterman, Sheldon J. Freedman, Sean P. Heron, Brian C. Mazzarella et autres

IP21-27 IsoPSA LARGE SCALE PROSPECTIVE VALIDATION STUDY: PERFORMANCE OF THE IsoPSA TEST IN PATIENTS AGED 50-69 YEARS

AARON J. MILBANK, Lawrence Belkoff, Paul E. Dato, Sheldon J. Freedman et autres

Preservation of sexual function with Optilume—a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia

Olivia R. Copelan, Jared L. Moss, Sheldon J. Freedman, Karl Coutinho et autres

BACKGROUND: The Optilume benign prostatic hyperplasia (BPH) catheter system is a novel minimally invasive paclitaxel-coated dilation system that has demonstrated substantial and durable results in urinary flow and symptoms. AIM: We now assess the impact of Optilume BPH procedure on sexual function. …

us, ca (code pays fourni par la source)

P2-13 PRELIMINARY RCT ANALYSIS OF MINIMALLY INVASIVE SURGERY VS. MEDICATION IN THE INITIAL TREATMENT OF BPH-ASSOCIATED LUTS

Philip P. Brodak, Shadi Tarazi, Prithipal Sethi, Michael Trotter et autres

You have accessJournal of UrologyParadigm-shifting, Practice-changing Clinical Trials in Urology (P2)1 May 2024P2-13 PRELIMINARY RCT ANALYSIS OF MINIMALLY INVASIVE SURGERY VS. MEDICATION IN THE INITIAL TREATMENT OF BPH-ASSOCIATED LUTS Philip Brodak, Shadi Tarazi, Prithipal Sethi, Michael Trotter, Dean Elterman, Sheldon Freedman, Sean …

Two-year long-term follow-up of treatment with the Optilume BPH catheter system in a randomized controlled trial for benign prostatic hyperplasia (The PINNACLE Study)

Steven A. Kaplan, Jared L. Moss, Sheldon J. Freedman

BACKGROUND: Patient outcomes were assessed 2 years after treatment with the Optilume BPH Catheter System, a minimally invasive surgical therapy for the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). METHODS: One-hundred forty-eight adult males with symptomatic …

us (code pays fourni par la source)

Optilume BPH: 2-Year Results from A Prospective Multicenter Randomized Clinical Trial for the Treatment of Benign Prostatic Hyperplasia (The PINNACLE Study)

Steven A. Kaplan, Jared L. Moss, Sheldon J. Freedman

Abstract Background Patient outcomes were assessed 2 years after treatment with the Optilume BPH Catheter System, a minimally invasive surgical therapy for the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH).Methods One-hundred forty-eight adult males with symptomatic …

us (code pays fourni par la source)

The PINNACLE Study: A Double-blind, Randomized, Sham-controlled Study Evaluating the Optilume BPH Catheter System for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

Steven A. Kaplan, Jared L. Moss, Sheldon J. Freedman, Karl Coutinho et autres

PURPOSE: The Optilume BPH Catheter System is a novel drug/device combination minimally invasive surgical therapy for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. The PINNACLE study is a prospective, randomized, double-blind, sham-controlled clinical trial evaluating the safety …

us, ca (code pays fourni par la source)

Reply by Authors

Steven A. Kaplan, Jared L. Moss, Sheldon J. Freedman, Karl Coutinho et autres

No AccessJournal of UrologyAdult Urology1 Sep 2023Reply by Authorsis a reply to letterEditorial Comment Steven A. Kaplan, Jared Moss, Sheldon Freedman, Karl Coutinho, Ning Wu, Mitchell Efros, Dean Elterman, Richard D'Anna, Osvaldo Padron, Kaiser J. Robertson, Samuel Lawindy, Sandeep Mistry, Neal Shore, …

us, ca (code pays fourni par la source)

12-MONTH OUTCOMES FROM A RANDOMIZED, DOUBLE-BLIND, SHAM CONTROLLED STUDY EVALUATING A NOVEL DRUG COATED BALLOON FOR THE TREATMENT OF BPH

Dean Elterman, Steven A. Kaplan, Jonathan G. Moss, Sheldon J. Freedman et autres

ca, us (code pays fourni par la source)

PD41-03 12-MONTH OUTCOMES FROM A RANDOMIZED, SHAM CONTROLLED STUDY EVALUATING A NOVEL DRUG COATED BALLOON FOR THE TREATMENT OF BPH

Steven A. Kaplan, Jared L. Moss, Sheldon J. Freedman, Karl Coutinho et autres

You have accessJournal of UrologyCME1 Apr 2023PD41-03 12-MONTH OUTCOMES FROM A RANDOMIZED, SHAM CONTROLLED STUDY EVALUATING A NOVEL DRUG COATED BALLOON FOR THE TREATMENT OF BPH Steven A. Kaplan, Jared Moss, Sheldon Freedman, Karl Coutinho, Ning Wu, Mitchell Efros, Dean Elterman, Richard …